🟢 ProMIS Neurosciences shares jump 7.7% on positive PMN310 human data from AAIC 2026

ProMIS Neurosciences is trading at $13.78 (7.7%) up in pre-market, driven by a significant clinical update.

• The company today announced the first human evidence of dose-dependent amyloid-beta oligomer (AβO) reduction by its lead Alzheimer's drug candidate, PMN310, presented at AAIC 2026.
• These positive findings from the Phase 1a trial demonstrated PMN310's strict oligomer selectivity and favorable pharmacokinetics, alongside its existing FDA Fast Track designation from July 2025.
• Investors are reacting to this pivotal data, which provides crucial insights into PMN310's potential as the PRECISE-AD Phase 1b trial continues to generate interest.